Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...
manilatimes12h
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...
Palatin Technologies, Inc. (AMEX:PTN) Q2 2025 Earnings Call Transcript
Palatin Technologies, Inc. (AMEX: PTN) Q2 2025 Earnings Call Transcript February 13, 2025 ...
Zacks.com on MSN7h
KLA Corporation Stock Up 21% Year to Date: Is It Still a Good Buy?
KLA Corporation KLAC shares have surged 21.5% in the year-to-date period, outperforming the broader Zacks Computer & Technology sector’s rise of 2.6% and the Zacks Electronics - Miscellaneous Products ...
Blue Bird Stock Is A Bargain, Not A Value Trap
Blue Bird Corporation remains a “Strong Buy” due to its solid backlog, strong funding, and undervaluation, despite recent ...
Hosted on MSN8h
Nu Skin Q4 Earnings Beat Estimates, Rhyz Revenues Increase Y/Y
Nu Skin Enterprises, Inc. NUS posted fourth-quarter 2024 results, with the top and bottom lines surpassing Zacks Consensus Estimate. Earnings increased and net sales declined year over year. For 2025, ...